Agilent Technologies (A) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Agilent Technologies (A)

134.41

+0.37 (0.28%)

as of Jul 14, 2026, 4:20:13 pm Market Open.

6 watching

Investor Insights

Jul 13, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Agilent Technologies has recently faced mixed reviews, with some analysts expressing concerns over the company's previous quarter performance, highlighting a need for a compelling narrative regarding its pharmaceutical segment. Despite this, there are signs of recovery; the company has reported a robust quarter showing 7% organic growth, indicative of a turnaround in its business trajectory. The driving forces behind this positive shift include an increase in re-shoring activities within the life sciences sector and the rising demand for certain medications that necessitate more complex hardware for production. Furthermore, the FDA's regulatory environment has been less challenging than anticipated, contributing to an optimistic outlook for Agilent in the life sciences market. Overall, the recent performance and market dynamics suggest that the company is on a path to recovery, although there remains some skepticism linked to its previous struggles.

Consensus

Mixed

Valuation

Fair Value

Similar

BMY

COMMENT

They report today. Last quarter was a bad miss. They need to tell a good story about pharma.

BUY

Is up 55% from its April lows. They just reported a strong quarter with 7% organic growth. The business is turning around, helped by re-shoring in life sciences, plus the rise of some medicine that require more hardware to produce. The FDA is less disruptive as expected. The life sciences sector looks attractive.

BUY

Shares popped over 2% after reporting a solid quarter last Wednesday .

BUY ON WEAKNESS

It just affirmed its forecast of 5-7% annual revenue growth and steady operating margin expansion. Trades at only 22x 2025 PE.

PAST TOP PICK

(A Top Pick Nov 24/22, Down 29%)

Sector has been impacted with economic slow down after Covid-19. Believes healthcare sector will be strong in the long term. Lab tools in high demand globally. Will continue to own shares. Well managed company.

TOP PICK

Consumables for labs. Green energy and pharmaceuticals creating all sorts of demand. Last quarter had 17% organic growth, pretty impressive. Guiding to 5-6% organic growth going forward. Underutilized balance sheet could be flexed for acquisitions. Growing dividend. Yield is 0.58%. (Analysts’ price target is $158.56)

BUY

It's been marching up for the last 16 months, doubling since the start of Covid. A lot of this rise came from Covid testing. Yesterday, they reported a top- and bottom-line beat, as revenues grew 26% YOY, driven by their pharma, chemical and energy businesses. He loves it. Amid sector rotations in the past year, this kept rising steadily.

PAST TOP PICK

(A Top Pick Jun 03/20, Up 55%) Great business. Involved in so many industries with secular growth. Underlevered balance sheet, so they'll be able to take advantage of opportunities.

PAST TOP PICK

(A Top Pick Jun 03/20, Up 48%) They've sold a rising number of consumables as medical schools reopen. They've increased revenue guidance for the year as businesses reopen. The valuation is reasonable. He expects them to buy companies in Asia to add to their growth.

TOP PICK

He likes this for their US dividend fund. They will benefit from the urgency to build labs to find a vaccine for COVID-19. An interesting market to be involved in. The space is very oligopolistic and the the company owns a 20% marketshare. Its balance sheet is under-levered he feels and a large amount of recurring revenue to replace lab components. Yield 0.79% (Analysts’ price target is $87.72)

BUY

Re-engineered itself to focus on its test measurement and instrument business. Very broad product line in that space. Moved manufacturing offshore. Really a play on R&D rather than the economy. If you want exposure nanotechnology, optics, Intermaxtic biotechnology, etc. this company has products going into all those areas.

TOP PICK

8.5% yield growth. They like the focus on Alberta. The company mainly has two businesses; one is trucking and the other is moving oil service equipment. Pay out ratio is around 65%. Lots of room for distribution increases. No debt on the balance sheet. Risks could be commodity prices or a slow down in the Alberta economy.( which he does not see happening) Paid $24-30.50.

PAST TOP PICK

(Top Short July 7/05. Down 11%.) It had fallen below the 200 day moving average and every rally that we had, failed to go higher than the 200 which indicated a negative trend. Historically this stock has an up tick at year end, but will then fall again.

WEAK BUY

In a long upward trend line, and you should never buy during this period. Currently, the stock is trying to break up. It could be a trade. If the stock violates the trend lines, be sure to get out.

DON'T BUY

Not a huge fan of this one. They seem to have trouble executing.

Showing 1 to 15 of 32 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Agilent Technologies (A) Frequently Asked Questions

What is Agilent Technologies stock symbol?

Agilent Technologies is a American stock, trading under the symbol A (previously A-N on Stockchase) on the New York Stock Exchange (A). It is usually referred to as NYSE:A or A

Is Agilent Technologies a buy or a sell?

In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on A (previously A-N on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Agilent Technologies.

Is Agilent Technologies a good investment or a top pick?

Agilent Technologies was recommended as a Top Pick by Joe Terranova on 2026-05-27. Read the latest stock experts ratings for Agilent Technologies.

Why is Agilent Technologies stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Agilent Technologies.

Is Agilent Technologies worth watching?

Agilent Technologies is followed by 6 investors on Stockchase and is a trending stock that is worth watching.

What is Agilent Technologies stock price?

On 2026-07-14, Agilent Technologies (A) stock closed at a price of $134.41.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Agilent Technologies (A)